

Studiekaracteristieken bij richtlijn Off-label geneesmiddelen 5-6-2023

Table 1 Characteristics of included studies

Author	Disease	Year of publication	Study design	Treatment arms (no. of patients)	Mean treatment duration [range], mo	Mean FU duration [range], mo	No. of patients (m/f)	Mean patients age [range], y	Previous treatments (no. of patients)	Mean weekly dose MTX [range]
Alkeraye	AA	2017	Prospective CS	<u>Pred + MTX</u> (14) Pred (6)	≥ 6	≥ 6	14	Unk [21-72]	Pred 500 mg/d; 3 d/mo for 3 mo (14)	Unk [10-20 mg]
Anuset	AA	2016	Retrospective CS	MTX	Unk	33 [6-81]	26 (8/18)	Unk	TCS (18), ICS (16), MNX (15), PT (14), DPCP (11), other (11)	Unk [15-20 mg]
Chartaux	AA	2010	Retrospective CS	MTX	Unk [6->24]	30	33 (9/24)	Unk	PUVA (19), OCS (10), CST bolus (5)	MTX
Droitcourt	AA	2012	Retrospective CS	MTX	19 [3-30] (median)	8 [7-20]	20 (8/12)	33 [14-57] (median)	TCS (13), MNX (14), T TAC (1), PT (4), Pred (1)	Unk [12.5 - 25 mg]
Firooz	AA	2013	Retrospective CS	MTX	Unk	14.4 [4-32]	10 (2/8)	29.6	Artificial hair transplant (1), AZA (2), clobetasol under occlusion (3), CST injection (1), DPCP (5), DTN (1), herbal	Unk [5 mg/wk - 37.5 mg/d]

									medicine (1), levamisole (1), MNX (9), PUVA (2), Sul (2), T dinitrochlorobenzene (5), zinc (4)	
Hammer-schmidt	AA	2014	Retrospective Co	MTX	Unk	13 [3-51]	31 (11/20)	40 [15-72]	T sensitisers (18), SCS (16)	Unk [10 -25 mg]
Joly	AA	2006	Retrospective CS	<u>Pred+MTX (16)</u> MTX (6)	Unk [9-27]	15	22 (7/15)	37.6	IV CS (4), OCS (9), PUVA (22), TAC (3), TCS (22)	Unk [15-30 mg]
Lim	AA	2017	Retrospective Co	MTX	7.025	Unk [12-20]	29 (16/13)	40.31 [16-65]	DPCP (2), Cry (8), CSTA (3), MPP (7), SCS (9), Sul (1), TCA sc (29), TCST (29), UVB (13)	14.5 mg [10- Unk]
Thi Van	AA	2019	Prospective Co	MTX	4	6	38 (31/7)	29.6	Unk	7.5 mg
Vano-Galvan	AA	2017	<u>MTX (10)</u> MTX+Pred (5)	Unk	Unk	15	Unk	Unk	Unk [15-25 mg]	<u>MTX (10)</u> MTX+Pred (5)
Chong	PedAA	2017	CS	MTX	Unk	Unk	14	Unk	TA (14)	0.2 mg/kg/d
Landis	PedAA	2017	Retrospective CS	MTX	Unk [1.5- Unk]	Unk	14 (4/10)	Unk [3-17]	Anthralin, excimer laser, IL or IM CST TCS, MNX, PT, Squaric Acid, Sul (No. Unk)	Unk [2.5-15 mg]
Lucas	PedAA	2016	Retrospective CS	MTX	Unk [32.4 - 37.32]	Unk [2-72]	5 (2/3)	Unk, ped	SCS, TCS (No. Unk)	Unk [17.5-25 mg]

Royer	PedAA	2011	Retrospective CS	MTX	14.2 (1-31)	Unk	14 (6/8)	14.7. (8-18)	Isoprinosine, OCS, PT, UVA (No. Unk)	18.9 mg [15-25]
Anderson	AD	2019	Retrospective CS	MTX	15.3	Unk	55 (25/30)	10.6 [3.0-19.5]	AZA (3), CSA (6), MPA (3), MTX (5), UVB (21)	Unk [0.37 - 0.45 (oral)/ - 0.37 - 0.5 (sc) mg/kg] (1)
Baum	AD	2019	Retrospective Co	MTX	Unk	Unk	19	Unk	Unk	Unk
Delcasso	AD	2018	Retrospective Co	MTX	21	Unk	20 (8/12)	39	PT and/or CSA (15)	Unk: initial mean dose 21 mg
Gerbens+	AD	2018	Open-label observational follow-up study	MTX (17) AZA (18)	Unk [Unk-60]	Unk	17 (10/7)	43.3	AZA (1), CSA (1)	Unk [10-22.5 mg]
Goujon	AD	2006	Retrospective CS	MTX	Unk [1-30]	Unk	20 (10/10)	26.3 [17-68]	Em (Unk), TCI (Unk), TCS (Unk)	Unk [7.5-25 mg]
Goujon	AD	2017	RCT	MTX (50) CSA (97)	6	Unk	50 (28/22)	32	TCS or TCI (50)	Unk [15 - 25 mg]
Hegazy	AD	2017	Retrospective Co	MTX	6	Unk	37	Unk	Unk	Unk [15-20 mg]
Ho	AD	2018	Retrospective CS	MTX	Unk	>18	>300	Unk	Unk	15 mg
Lyakhovitsky	AD	2010	Retrospective CS	MTX	Unk [2-3]	Unk [2-24]	20 (12/8)	51.8 [20-85]	AH, CSA (3), PT (11), SCS (15), TCS	Unk [10-25 mg]
Mittal	AD	2011	CS	MTX	Unk [12-Unk]	Unk	15 (10/5)	Unk [30-60]	Unk	Unk [10-15 mg]

Politiek	AD	2016	Retrospective CS	MTX	7.4	Unk [Unk-2]	89 (53/36)	50.7	Or immunosuppressive drugs (62)	13.6 mg [5-25]
Purvis	AD	2019	Retrospective CS	MTX	17 (median)	29	43 (21/22)	Unk [2-16]	CSA (2), PT (2), Pred (1), Systemic treatment (5)	0.3 mg/kg (median)
Rahman	AD	2014	Retrospective CS	MTX	12	Unk	30	8 [2-17] (median)	TA (30)	0.5 mg/kg [Unk-15]
Roekevisch+	AD	2018	Open-label observational follow-up study	AZA (18) MTX (17)	Unk [Unk-24]	Unk	17 (10/7)	43.3	Unk	14.5 mg [10-22.5]
Schram	AD	2011	RCT	AZA (22) MTX (20)	3	3	20 (10/10)	43	CSA (Unk)	17.5 - 20 mg (week 12 and week 24)
Shah	AD	2018	Retrospective Co	MTX	36.8 [1-132]	Unk	41 (22/19)	45 [19-90]	AB (3), AZA (7), CSA (5), IMCS (12), MMF (1), MTX (3), OCS (17), other (1), PT (11)	Unk [7.5-25 mg]
Syed	AD	2009	Prospective CS	Placebo (30) MTX (30)	3	Unk	30	Unk	Unk	0.1 mg/kg [5-7.5]
Vedie	AD	2016	Retrospective Co	MTX	20.4 - 27.9	57.8	35	Unk	AZA, TCS (No.Unk)	Unk [15-20 mg]
Weatherhead	AD	2007	Prospective CS	MTX	6	3	12 (7/5)	37	TCS (12)	Unk [5-22.5 mg]
Zoller	AD	2008	Retrospective CS	MTX	3-28	Unk	9 (6/3)	75 [52-85]	CSA (Unk), PT (Unk), SCS (Unk), TCI	Unk [5-20 mg]

									(Unk), TCS (9)	
Deo	PedAD	2014	Retrospective CS	MTX	9.5 [2-38]	Unk	31 (14/17)	Unk	TA (31), PT (15), OCS (9), Or A (14), other (1)	0-5 Y: 7.5 mg 6-14 Y: 10 mg 15-18 Y: 15 mg (all median)
Dvorakova*	PedAD	2017	Retrospective CS	MTX	17.2 [5-33]	Unk [Unk-14]	47 (32/15)	Unk	AB (18), AZA (8), CSA (8), NB-UVB PT (4), IVIG (1), SCS (16)	3.4 mg/kg
El-Khalawany	PedAD	2013	Randomised head-to-head trial	<u>MTX (20)</u> CSA (20)	3 [Unk]	3 [Unk]	20 (12/8)	MTX: 11.2 [8-14]	TA (40), PT (Unk)	MTX: 7.5 mg/wk [Unk],
Knopfel	PedAD	2018	Retrospective CS	MTX	12.6	Unk	28 (24/4)	7.8 [2-18]	AZA (1), CSA (6), Or AB (Unk), OCS (21), TCS (28), T AB (Unk)	Unk [0.2 - 0.5 mg/kg]
Roberts	PedAD, NE	2010	Retrospective CS	MTX	10.5 [3-30]	9 [1-22]	25	7 (3-16)	MTX (90)	Unk [5-15 mg]
Taieb	PedAD	2019	Retrospective CS	MTX	14 (median)	25 (median)	26 (13/13)	12 (median)	CS (12), other systemic immunosuppressive (4), PT (23)	Unk [0.3-0.6 mg/kg]
Kalyoncu	AO SD	2016	Retrospective Co	<u>CS+MTX (117)</u> CS+HCQ+ MTX (85)	Unk	Unk	Unk	Unk	Unk	Unk
Bakker	BP	2013	Retrospective CS	MTX	4	26.4 [3-96]	6 (Unk)	Unk	Unk	Unk [5-15 mg]

Bara	BP	2003	CS	MTX	Unk	11.4 [4-23]	16 (7/9)	84.6	Unk	Unk [10-15mg]
Dereure	BP	2002	Prospective CS	MTX	Unk [2-Unk]	Unk [6 - Unk]	18 (7/11)	77.8	Potent TCS 2-3 wks (18)	Unk [7.5-12.5 mg]
Du-Thanh	BP	2011	Retrospective CS	MTX	8.48 [1-18]	Unk	70 (30/40)	82.7 [50-97]	Unk	9.8 mg
Heilborn	BP	1999	Prospective CS	MTX	Unk [3-24]	24	11 (4/7)	81 [73-91]	TCS (Unk)	Unk [5-12.5 mg]
Kjellman	BP	2008	Retrospective CS	MTX (61) MTX+pred (37)	Unk	26 (median) [0.5-77]	98 (39/59)	Unk	Unk	Unk [2.5-17.5 mg]
Kremer	BP	2017	Retrospective CS	MTX	Unk	Unk	6	Unk	CS (Unk)	Unk
Kwatra	BP	2013	Retrospective CS	MTX	25.3	Unk [20.4-66]	16 (8/8)	71.4 [30-94]	Unk	Unk [2.5-15 mg]
Paul	BP	1994	Retrospective CS	MTX	Unk [10-39]	Unk [10-44]	8 (4/4)	73.5 (63-87)	AB (3), TCS (3), SCS (8)	Unk [5-20 mg]
Click	DM	2013	Retrospective CS	MTX	Unk [4-Unk]	Unk	8 (0/8)	39 [25-60]	IVIG (1), MPA (2), HCQ (6), AZA (1)	Unk [15-25 mg]
Hornung	DM	2012	Retrospective CS	MTX	Unk [2-3]	Unk	11 (3/8)	61 [46-84]	SCS (11), AZA (4), MPA (1)	14.91 mg
Kasteler	DM	1997	Retrospective CS	MTX	Unk [3-22]	Unk	13 (0/13)	48 [22-77]	AZA (1), Chlorambucil (1), CQ (7), HCQ (6), Pred (2), Quinacrine (2)	18.5 mg [2.5-30] (mean maximal dose)
Ramanan	DM	2005	Retrospective Co	MTX	45.5 (median)	48	31 (11/20)	8.4	Unk	15 mg/m ²

Ruperto	DM	2016	RCT	Pred (47) Pred+CSA (46) Pred+MTX (46)	Unk	35.5 (median)	46 (16/30)	Unk	Pred (3)	15-20 mg/m2
Zieglschmid	DM	1995	Retrospective CS	MTX	1.8-68.5	Unk	10 (1/9)	Unk [27-79]	Pred (8)	8 mg (mean initial) - 15.92 (max)
Chen	E	2016	Co	MTX	22 [2-93]	Unk	41 (27/14)	49 [18-83]	PT (14), CSA (30), MPA (9), AZA (7)	Unk [10-25 mg]
Shaffrali	E	2003	Retrospective CS	MTX	Unk [3-18]	Unk	5 (2/3)	74.4 [67-83]	AZA, OCS, PT, TCS (No. Unk)	Unk [2.5-12.5 mg]
Téart	E	2011	Retrospective CS	MTX	2.6	12	15 (11/4)	78	CSA (1), Pred (1), PT (5), TCS (15), TA (3)	9.7 mg
Patel	All CE	2018	Retrospective Co	MTX	Unk [3.2-53.1]	Unk	32	Unk	Unk	Unk [Unk-30 mg]
Politiek	HE	2016	Retrospective Co	MTX	4.6	Unk [Unk-2]	42 (29/13)	53.2	Systemic treatment (7)	Unk [5-20 mg]
Berianu	EF	2015	Retrospective CS	MTX	31.4 [12-84]	Unk [12-36]	16 (8/8)	52 [30-75]	Pred (13), AZA (3), HCQ (2)	Unk
Lebeaux	EF	2012	Retrospective CS	MTX	24.7 [5-93]	Unk	12	Unk	OCS (12)	Unk [15-30 mg]
Mertens	EF	2016	Prospective Co	MTX	5	Unk	12 (1/11)	Unk [37-69]	MTX (6), SCS (6)	288 mg/kg/month (median)
Hossain	ENL	2013	Prospective CS	MTX	Unk [24-30]	24	9 (7/2)	34 [23-52]	Clofazamine (9), Pred (9)	7.5 mg
Naka	GA	2018	Retrospective Co	MTX	Unk [Unk-60]	Unk [Unk-72]	11 (2/9)	60.7	Ada, AZA, dapson, kenalog injections, PT,	Unk [12.5-15 mg]

									SCS, TA, TCS, UVB (No. Unk)	
Arfi	LE	1995	CS	MTX	Unk [1-24]	Unk	16	33 [16-48]	Unk	Unk [7.5-10 mg]
Böhm	LE	1998	Retrospective CS	MTX	Unk [1-12]	Unk	12 (6/6)	53 [28-86]	AZA (1), CQ (5), SCS (9), TCS (2)	Unk [10-25 mg]
Böhm	LE	2003	Retrospective CS	MTX	Unk [0.25-25]	27.9 [6-62]	22 (9/13)	46.5 [27-74]	Pred, antimalarials (No. Unk)	Unk [10-30 mg]
Carneiro	LE	1999	RCT	MTX (20) Placebo (21), 28 with skin involvement	6	Unk	41 (2/39)	32.1	Antimalarial, immunosuppressive	Unk [15-20 mg]
Fruchter§	LE	2017	Retrospective CS	MTX	Unk	58	27	Unk	HCQ sulphate (No. Unk), antimalarial (No. Unk)	16.6 mg
Gansauge	LE	1997	Prospective CS	MTX	6	Unk	10	Unk	Antimalarials, Pred (No. Unk)	15 mg
Islam	LE	2012	RCT	MTX (13) CQ (29)	6	6	13 (0/13)	24	Unk	10 mg
Kan	LE	2016	Retrospective Co	MTX	Unk	48	27	Unk	None	Unk
Wenzel	LE	2005	Retrospective CS	MTX	25.6 [2-67]	Unk [Unk-24]	43 (13/30)	52 (19-86)	TA (43), antimalarials (31), AZA (6), dapsone (2), mmf (4)	Unk [7.5-20 mg]
Chauhan	LP	2018	Prospective CS	MTX (15) MTX + TCA (15)	Unk [≤ 4]	Unk [≤ 8]	30 (9/6, MTX), (8/7, MTX	MTX: 46.3 3 [40-52]	Unk	Unk [Unk - 0.3 mg/kg]

							+ TCA)	MTX + TCA: 45.5 3 [36- 55]		
Ilyas	LP	2016	Prospective Co	MTX	3	3	55 (23/3 2)	37 [22-65]	Unk	15 mg
Kanwar	LP	2013	Prospective CS	MTX	Unk [Unk- 24]	3	24 (8/16)	37.4 [9- 63], 2 childr en [Unk]	Unk	Adults: 15 mg, children 0.35 mg/kg
Lajevardi	LP	2016	Prospective CS	MTX	3	3	18 (5/13)	53.8 [30- 65]	MMF (4), SCS (11), TCI (3), TCS/IL CST (13)	15 mg
Malekzad	LP	2012	Prospective Co	MTX	Unk [8- Unk]	6	18 (8/10)	51.1 [22- 80]	Unk	Unk [≤10 mg]
Torti	LP	2007	Retrospective CS	MTX	Unk	27	18	Unk	Unk	Unk [2.5- 12.5 mg]
Turan	LP	2009	Retrospective CS	MTX	Unk [1-4]	6	11 (3/8)	44.2 [27- 55]	SCS (4), TCS (7)	Unk [15-20 mg]
Kortekangas- Savolainen	LP, vulvova ginal	2007	Retrospective CS	MTX	Unk [6-36]	Unk [12- 48]	5 (0/5)	57.6 [45- 65]	Repeated vaginal dilatations (5), TAC (2), tetracycline (1), TCS (2)	7.5 mg
Babahosseini	LPP	2019	Retrospective CS	MTX	Unk	Unk	30	Unk	Unk	Unk
Bakhtiar	LPP	2018	RCT	MTX (79) OCS (79)	2 [Unk]	Unk	79 (47/3 2)	Unk	Unk	10 mg

Bulbul baskan	LPP	2017	Retrospective CS	<u>MTX (10)</u> CSA (6)	Unk [3-6]	Unk	10 (2/8)	Unk	Unk	Unk [10-15 mg]
Kerkemeyer	LPP	2018	Retrospective CS	MTX	Unk	Unk	7	Unk	Unk	Unk
Naeini	LPP	2017	RCT	<u>HCQ (14)</u> MTX (15)	6	Unk	15 (2/13)	44.9	Ac (2), CSA (4), isotretinoin (2), pioglitazone (1) SCS (8), TCS (15)	15 mg
Karadag	LS	2018	Prospective CS	MTX	12.6 [3-18]	10.6 [6-17]	6 (0/6)	53 [46-63]	Ac (2), Colchicine (3), TCS (6), UVA (2), NB UVB (1)	7.5 mg
Kreuter	LS	2009	Retrospective CS	MTX	>6	4.7 [3-8]	7 (1/6)	67.6 [50-80]	Ac (1), NB-UVB PT (1), penicillin (3), T calcipotriene (1), TCS (7), UVA PT (3), PUVA (2)	15 mg
Fernandez-de-Misa	LyP	2018	Retrospective CS	MTX	Unk	52 [1-277] (median)	51	Unk	Unk	Unk [≤20 mg]
Bulur	M/PedM	2017	Retrospective CS	MTX	Unk	5	14	Unk	Colchicine, SCS, TCS (No. Unk)	Unk
Christen-Zaech	M/PedM	2008	Retrospective CS	MTX	19.9 [3-52]	Unk	39	9.8	Unk	Unk [0.3-0.5 mg/kg till 35 mg/wk]
Kreuter	M	2005	Prospective CS	MTX	9.8 [6-25]	>6	15 (6/9)	50.7 [18-73]	Penicillin (7), PUVA (6), SCS (4), TCS (3)	15 mg

Kroft	M/EF/SS	2009	Retrospective Co	<u>MTX (47)</u> MTX+CS (11)	Unk [10-16]	Unk	58 (18/40)	40 [13-67]	AB (7), antimalarials (5), AZA (1), Em (3), isotretinoin (3), penicillamine (5), PT (4), TCS (16), TCA lesional injection (1)	Unk [15-25 mg]
Mertens	M	2016	Retrospective Co	MTX	12.3 [1-65.3]	Unk	107 (30/77)	Unk	Unk	15 mg [5-26.9 mg]
Platsidaki	M	2017	Retrospective CS	MTX	Unk [Unk-12]	21	20 (3/17)	Unk	HCQ (3), penicillamine (2), PUVA (20), SCS (20), TCI (20), TCS (20), vit D analogues (20)	15 mg
Seyger	M	1998	Prospective CS	MTX	6	0	9 (2/7)	47.8 [34-71]	Systemic treatment, TA (No. Unk)	Unk [15-25 mg]
Shahidi	M	2018	CS	MTX	18	Unk	33 (5/28)	29 [10-61] (median)	Unk	Unk [15 mg- Unk]
Wlodek	M	2018	Retrospective CS	MTX	Unk	Unk	8 (0/8)	62 (52-69) (median)	Bath PUVA (3), HCQ (3), Pred (3), TL-01 (1)	Unk [2.5-30 mg]
Cox	PedM	2008	Retrospective CS	<u>MTX (9)</u> CSA (1)	23 [10-36]	Unk	9	7.4 [4-16]	D-penicillamine (2), CSA (2), SCS 30 mg/kg/d, 3 d/mo for 3 mo (10)	0.3 mg/kg

Fitch	PedM	2006	Retrospective CS	MTX	4-7	>6	17 (6/11)	7.3	TCI (2), TCS (11), T vit D (11)	Unk [12.5-25 mg]
Koch	PedM	2013	Retrospective CS	MTX	19.6 [5.8-52.8]	55.2 [11.3-162]	17 (9/8)	15.2 [4-25]	Unk	9.12 mg [2.5-15]
Li	PedM	2019	Prospective Co	MTX mono (12) MTX with iv Cst (23) MTX with OCS (9)	12	Unk	44 (13/31)	12.6	Systemic treatment (7)	Unk [1 mg/kg, max 25 mg]
Mirsky	PedM	2012	Retrospective Co	MTX	28.8	Unk [7.3-7.0]	90 (32/58)	10.2	MTX (90)	Unk [Unk-15 mg]
Piram	PedM	2013	Retrospective CS	MTX	24	Unk	24	Unk	Unk	0,5 mg/kg
Rattanakaemakorn	PedM	2017	Retrospective CS	MTX	Unk [2-Unk]	Unk [7-33.6]	7 (3/4)	11.8	TCS (1)	Paediatric dose; Unk [2.5 mg-Unk], adult dose; Unk [10 mg-Unk]
Torok	PedM	2012	Prospective Co	MTX	36	36.4	36 (11/25)	7.9	CSA (2), MTX (1), TA (25)	1 mg/kg
Uziel	PedM	2000	Prospective CS	MTX	Unk [2-13]	Unk [8-30]	10 (4/6)	6.8 [2-12]	D-penicillamine (1), naproxen (1), Pred (2), TCS (1)	Unk [0.3-0.6 mg/kg]
Weibel	PedM	2006	Retrospective CS	MTX	Unk	35	34 (11/23)	8.2 [2.3-15.2]	PT (1), systemic therapy (1), TCS (10)	Unk [10-12.4 mg/m2]

Zulian	PedM	2011	RCT	MTX (46) Placebo (24)	Unk [Unk-12]	40.3 [3-72]	46 (34/12)	9	Antimycotics/AB (13), CSA (1), D-penicillamine (6), TCS (22)	15 mg/m2 [Unk-20 mg]
Zulian±	PedM	2012	Prospective Co	MTX	27.5 [Unk -72]	Unk	65 (16/42)	9.4 [Unk]	Antimycotics/AB (13), CSA (1), D-penicillamine (6), TCS (22)	15 mg/m2 [Unk-20 mg]
Torrelo	Pa	2017	Retrospective CS	MTX	Unk [3-Unk]	Unk	5 (1/4)	4.3 [1.5-8]	Unk	Unk [0.3-0.4 mg/kg]
Moustafa	PD	2015	Retrospective CS	MTX	14.5 [2-65]	65	12	63.5 (median)	Anti-pruritics (6), doxepin (2), neurontin (1), Pred (7)	Unk [2.5-10 mg]
Rivitti	PF	1973	Retrospective CS	MTX	Unk	Unk	8 (2/6)	24	MTX (8), OCS (Unk)	Unk [20-37.5 mg]
Spring	PN	2014	Retrospective CS	MTX	Unk [2-24]	Unk	13 (4/9)	75.8	Antipruritic agents, PT, TCS (No. Unk)	Unk [7.5-20 mg]
Egan	PPP	1999	Retrospective CS	MTX	Unk [1-Unk]	Unk [1-Unk]	5 (4/1)	50 [39-62]	SCS (4), TCS (5), PUVA (3), CSA (1), ET (1)	Unk [12.5-22.5 mg]
Kleitman	Pr	2018	Retrospective CS	MTX	Unk	16 [2-108] (median)	39 (16/23)	62 [28-94] (median)	Ac (4), AH (34), AZA (1), Capsaicin (1), CSA (4), Em (28), HCQ (1), MMF (1), Naltrexone (2), O CS (3), Pregabalin (5), PT (22), T TAC (10), TCS (38),	15 mg [5-25]

									Thalidomide (9)	
Sharma	PrD	2007	Retrospective CS	MTX	Unk [6- Unk]	Unk	7	Unk	TCS (7), sunscreens (7)	15 mg
Allison	PRP	2002	CS	MTX	Unk	Unk	5	Unk	Unk	Unk
Chapalain	PRP	1999	Retrospective CS	MTX	12.1 [4.5- 19.5]	Unk	5	67 [45-87]	AC (2), TCS (5), PUVA therapy (1)	Unk [15-25 mg]
Dicken	PRP	1994	CS	MTX	6 [2-12]	Unk	8 (5/3)	Unk [35-74]	Vit A (3), isotretinoin (3)	Unk [10-25 mg]
Knowles	PRP	1970	Retrospective CS	MTX	Unk [4-7]	Unk	6 (6/0)	48.3 [40-60]	Pred (2)	Unk [2.5-5mg/d till 75mg/w k]
Baum	PV	2012	Retrospective CS	MTX	31 [6-96]	Unk [6-30]	30 (6/24)	54 [35-78]	AZA (18), dapsone (14), CSA (3), CP (2), MPA (1), IVIG (2)	15 mg
Lever	PV	1972	CS	<u>Pred -> MTX</u> (15) MTX -> pred (9)	Unk [10-106]	Unk	24	51.2 [20-79]	Pred, MTX (No. Unk)	Unk
Mashkilleyson	PV	1988	CS	MTX	Unk	Unk	53	Unk	Unk	Unk [25-50 mg (also in daily dosage)]
Peck	PV	1971	Retrospective CS	MTX	Unk	Unk [4-204]	13 (3/10)	Unk [18-76]	CST (13)	Unk [10-50 mg]

Smith	PV	1999	Retrospective CS	MTX	3	Unk [6- Unk]	9 (8/1)	59	AZA (Unk), CP (Unk), Pred (9)	Unk [7.5-17.5 mg]
Tran	PV	2013	Retrospective CS	MTX	Unk [3- Unk]	Unk [26- Unk]	23 (11/1 2)	54	AZA (3), dapsone (2), etanercept (1), IVIG (2), MMF (7), Pred (23), rituximab (2)	Unk [7.5-35 mg]
Lower	Sar	1995	Prospective CS	MTX	Unk [24- Unk]	Unk [Unk- 84]	22	39	Antimalarial agents (Unk), nonsteroidals (Unk), Pred (3)	Unk [≤15 mg]
Veien	Sar	1997	Co	MTX	23 [1-72]	Unk	16	51 [36-68]	Unk	Unk [Unk-25 mg]
Schanz	Sci	2013	Prospective Co	MTX	Unk	Unk [6-12]	22 (6/16)	52 (med ian)	Unk	15 mg
Breuckmann	SD	2005	Retrospective CS	MTX	6	Unk	7 (5/2)	56 [39-65]	Unk	25 mg
Herrick	SS	2017	Prospective Co	MTX (65) MMF (118) CP (87)	24	Unk	65 (15/5 0)	Unk	Unk	Unk [20-25 mg]
Pope	SS	2001	RCT	MTX (35) Placebo (36)	12	18 (med ian)	35 (4/31)	47	CST (10)	Unk [10-17.5 mg]
Sumanth	SS	2007	Prospective CS	MTX	Unk [6-12]	Unk	33 (4/29)	31 [17-51]	Unk	15 mg
Van den Hoogen	SS	1996	RCT	MTX (17) Placebo (12)	24	24	17	52 [32-75]	Colchicine (1), penicillamine (10), Pred (7), NSAID's (6)	15 mg

Leducq	Ur	2019	RCT	<u>MTX (39)</u> Placebo (36)	4.5	2	39 (11/28)	46.4	Colchicine (8), corticosteroids (22), montelukast (19)	Unk [0.2-0.25 mg/kg]
Perez	Ur	2010	Retrospective CS	MTX	Unk	Unk	16 (5/11)	49 [30-75] (median)	AZA (9), colchicine (4), CSA (14), doxepin (6), H1-AH (16), HCQ (6), IVIG (3), montelukast (12), sedating AH (13), Sul/Dapsone (7)	Unk [10-15 mg]
Sagi	Ur	2011	Retrospective CS	MTX	4.5	8.3	8 (2/6)	8	AH (8), colchicine (Unk), dapsone (Unk), doxepin (Unk), IV hydrocortisone (4), Or Pred (1)	15 mg
Sharma	Ur	2014	RCT	<u>MTX (14)</u> Placebo (15)	3	3.5 [0.5-9]	14 (6/8)	34.21	AH (14)	15 mg
AlGhamdi	Vi	2013	Prospective CS	MTX	6	9	6 (4/2)	29	Unk	25 mg
Singh	Vi	2015	Randomized comparative study	<u>CST (25)</u> MTX (25)	8	Unk	25	38.6	Unk	10 mg

* 4 patients (AB 3, AZA 1, CSA 1) received concomitant systemic medication. Since this number is low compared to the total number of patients, we still included this study.

§ This study reported an inconsequent number of patients; 26 patients participated, but from 23 patients AE's were reported and from 19 patients effectiveness was reported.

+ Follow-up study from Schram (2011)

± Follow-up study from Zulian (2011)

See also the abbreviation list on page **Fout! Bladwijzer niet gedefinieerd..**